What are the diagnostic tests for Lymphogranuloma Venereum (LGV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnostic Testing for Lymphogranuloma Venereum (LGV)

The diagnosis of LGV requires nucleic acid amplification testing (NAAT) for Chlamydia trachomatis followed by LGV-specific discriminatory testing to identify L1, L2, or L3 serovars, combined with serological testing when available. 1, 2

Primary Diagnostic Approach

Step 1: Initial NAAT Testing

  • Obtain specimens from the site of infection (genital ulcer, rectal swab for proctitis, or urethral/cervical swab) and test using standard commercial NAAT platforms for Chlamydia trachomatis 1, 3
  • Standard NAATs will detect C. trachomatis but cannot distinguish LGV serovars (L1-L3) from non-LGV serovars 4
  • For men who have sex with men (MSM) with proctitis symptoms, rectal swabs are the primary specimen 3, 2

Step 2: LGV-Specific Confirmatory Testing

  • Any positive C. trachomatis NAAT should be confirmed with an LGV discriminatory NAAT to identify L1, L2, or L3 serovars 2
  • These discriminatory tests are typically available only through reference laboratories or public health laboratories 3, 5
  • Critical caveat: LGV-specific testing is not widely available in most clinical settings 5

Serological Testing

Complement Fixation (CF) Test

  • CF titers ≥64 with appropriate clinical presentation suggest LGV, with sensitivity of 80% at 2 weeks 4, 1

Microimmunofluorescence (MIF) Test

  • MIF titers ≥256 with appropriate clinical presentation suggest LGV 4, 1
  • Serological testing provides supportive evidence but should not be used as the sole diagnostic method 6

Clinical Diagnosis When Testing Unavailable

When LGV-specific confirmatory testing is not available, diagnosis is made by exclusion of other causes combined with clinical presentation 6:

  • Tender unilateral inguinal/femoral lymphadenopathy in heterosexual men 6, 1
  • Proctocolitis or proctitis in MSM or women, with symptoms resembling inflammatory bowel disease 1, 3
  • History of self-limited genital ulcer at inoculation site (often no longer present when patient seeks care) 6, 1

Key Clinical Pitfall

  • Approximately 25% of anorectal LGV infections in MSM are asymptomatic, so testing should be performed even without symptoms in high-risk populations 2
  • The ratio of genital to anorectal LGV infections in MSM is 1:15, making rectal testing critical 2

Practical Algorithm

  1. Patient with proctitis/proctocolitis or inguinal lymphadenopathy: Obtain NAAT for C. trachomatis from appropriate site 3

  2. If NAAT positive: Send specimen for LGV discriminatory testing if available 2

  3. If discriminatory testing unavailable: Obtain serological testing (CF or MIF) and treat empirically for LGV if clinical presentation is consistent 3, 5

  4. All patients with rectal chlamydial infection AND signs/symptoms of proctitis should be tested for LGV or treated empirically 3

Additional Diagnostic Considerations

  • Cell culture can isolate L strains but has only 30% sensitivity and requires specialized media 4, 7
  • Histopathology of lymph node biopsy is non-specific and not recommended as primary diagnostic method 7
  • Buboes may require aspiration through intact skin for both therapeutic and diagnostic purposes 6

References

Guideline

Lymphogranuloma Venereum Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

2019 European guideline on the management of lymphogranuloma venereum.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2019

Research

Lymphogranuloma Venereum 2015: Clinical Presentation, Diagnosis, and Treatment.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015

Research

Treatment of lymphogranuloma venereum.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007

Research

[Lymphogranuloma venereum].

Sante (Montrouge, France), 1998

Related Questions

What is the treatment for Lymphogranuloma venereum (LGV)?
What is the appropriate evaluation and treatment for a 26-year-old male whose most recent sexual encounter was with his relative, concerning possible lymphogranuloma venereum?
What is the recommended workup and treatment for a patient trying to conceive who had unprotected intercourse with a relative 1.5 weeks ago and has cat exposure without scratches, concerning possible lymphogranuloma venereum?
In a 30-year-old sexually active woman with a painful genital vesicle, bilateral inguinal lymphadenopathy, a negative Tzanck smear, and a negative Venereal Disease Research Laboratory (VDRL) assay, which medication is most appropriate?
What is the appropriate doxycycline regimen (dose, duration, contraindications, counseling, and partner treatment) for an adult non‑pregnant woman with vaginal bumps and normal renal/hepatic function?
What is the preferred antibiotic (ABx) regimen for a stoma site infection with green drainage?
Do statins (HMG-CoA reductase inhibitors) cause gastrointestinal (GI) bleeding?
Can I restart Suboxone (buprenorphine/naloxone) twice a day (bid) now and at 2100, then resume the regular schedule of 0900 and 2100 the next day if a dose is missed?
Can ceftriaxone be given to patients with pneumonia, mild pleural effusion, and Chronic Kidney Disease (CKD)?
What is the diagnosis and treatment plan for a patient with glycosuria (glucose in the urine), hematuria (blood in the urine), and proteinuria (protein in the urine), with a urinalysis showing hyperglycemia (elevated glucose) and occult blood?
What is the management approach for stable pleural-based opacities (persistent chest x-ray findings) over a year?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.